# TGRX-678 Phase I Oral Pharmacokinetic Study

> **NCT06697899** · PHASE1 · COMPLETED · sponsor: **Shenzhen TargetRx Co., Ltd.** · enrollment: 76 (actual)

## Conditions studied

- Chronic Myeloid Leukemia

## Interventions

- **DRUG:** TGRX-678

## Key facts

- **NCT ID:** NCT06697899
- **Lead sponsor:** Shenzhen TargetRx Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-11-24
- **Primary completion:** 2025-01-06
- **Final completion:** 2025-02-20
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2025-05-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06697899

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06697899, "TGRX-678 Phase I Oral Pharmacokinetic Study". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06697899. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*